This study evaluates whether NSAID peritendinous or ligament injections at acute sprain sites can relieve pain and restore function.
Forty patients will be randomly assigned to either the injection or oral NSAID group. Pain will be assessed subjectively using the Numeric Pain Rating Scale and objectively through pressure pain threshold measurements. Functional outcomes (DASH for the upper limb, FADI for the lower limb) will be evaluated before treatment and at 3 days, 1 week, and 4 weeks post-treatment.

开始日期2025-02-10

申办/合作机构

Taipei Municipal Wanfang Hospital

NCT06783465

/ RecruitingN/AIIT

AI-Driven Generative Content and Precision Dynamic Executive Function Cognitive Digital Therapeutics System for Dementia Management

The study would investigate the effect of a cognitive digital therapeutics system. The intervention group would receive three digital therapeutics sessions per week for 8 weeks, while the control group would receive usual care. Evaluations would be done at baseline, week 8, and week 16.

开始日期2025-02-01

申办/合作机构

Taipei Municipal Wanfang Hospital

NCT06862297

/ RecruitingN/AIIT

Prospective Study on Concurrent Use of Multiple Polysomnography (PSG) Parameters and a Novel Ultrasonic Jaw Tracking Device in Patients with Sleep Apnea

Obstructive sleep apnea (OSA) affects over 936 million adults worldwide, leading to significant morbidity and reduced quality of life. Traditional diagnostic methods such as polysomnography (PSG), although effective, rely on hospital equipment and human resources and are not widely accessible. Emerging technologies such as the jaw tracking device developed by Sunrise have appeared, using gyroscopes and accelerometers to monitor jaw movements during sleep, showing high diagnostic accuracy compared to PSG. These devices use AI algorithms, providing a practical alternative for OSA diagnosis and monitoring. However, due to the high hardware cost of Sunrise and its rental-based business model, there are logistical challenges and limited monitoring capabilities. This prospective clinical study aims to offer the same capabilities through a novel ultrasonic transmitter for tracking jaw movements during sleep, which can be directly received by using a smartphone microphone, reducing the complexity of setup operations. This study will evaluate the sensitivity of the ultrasonic jaw tracking device in detecting apnea and compare it with PSG standards, developing a deep learning AI-driven algorithm to analyze data from jaw movements, breathing sounds, and apnea-related arousal events, as a basis for continuous home monitoring and evaluation of treatment effects for OSA patients.

开始日期2024-09-19

申办/合作机构

Taipei Municipal Wanfang Hospital

100 项与 Taipei Municipal Wanfang Hospital 相关的临床结果

登录后查看更多信息

0 项与 Taipei Municipal Wanfang Hospital 相关的专利（医药）

登录后查看更多信息

353

项与 Taipei Municipal Wanfang Hospital 相关的文献（医药）

2025-04-21·Cancer Research

Abstract 788: QT prolongation induced by CDK-4/6 inhibitors in breast cancer: A prospective cohort study utilizing 12-hour continuous ECG monitoring

作者: Chang, Wei-Wen ; Liu, H-Eugene ; Yu, Hsin-Hsien ; Liao, Tzu-Yao ; Hsieh, Mao-Chih ; Hsieh, Wan-Chen ; Hsiao, Ping-Kun ; Chiou, Tzeon-Jye ; Lee, Chih-Hsin ; Chang, Chia-Lun

AbstractCDK 4/6 inhibitors improve survival in HR+ and HER2 breast cancer patients but carry risks of QT prolongation. Single ECG readings may be unreliable. This study assesses QT prolongation via 12-hour ECG monitoring for three CDK 4/6 inhibitors.Methods:A prospective cohort study (Apr 2023-Aug 2024) included HR+, HER2- breast cancer patients receiving CDK 4/6 inhibitors. Exclusions were QTc >500 msec and persistent Af. Ribociclib/Palbociclib followed a 21/7 regimen; Abemaciclib was continuous. ECG monitoring occurred pre-treatment and on day 14 (Ribociclib/Palbociclib) or day 14 only (Abemaciclib). ECGs were recorded from 8 PM-8 AM and stored on the PCA 500 cloud. Drug blood concentrations were measured on day 8, with dose adjustments as needed.Results:From July 16, 2023, to July 31, 2024, 33 patients were included: Ribociclib (N=19), Abemaciclib (N=9), and Palbociclib (N=5). Case 36 underwent testing at 600 and 400 mg Ribociclib due to QT prolongation.• Ribociclib: Median baseline QTcF was 422 msec, rising to 431 msec (400 mg, N=7) and 440 msec (600 mg, N=13) post-treatment. QTcF Max >500 msec increased from 23% to 54% in the 600 mg group.• Palbociclib: Median QTcF rose from 431 msec (washout) to 439 msec (100 mg, N=4) and decreased to 421 msec (125 mg, N=4). QTcF Max >500 msec rose from 20% to 40% post-treatment.• Abemaciclib: Post-treatment QTcF medians were 425 msec (100 mg, N=1), 433 msec (150 mg, N=5), and 434 msec (alternative 150 mg, N=3). QTcF Max >500 msec increased to 56% post-treatment.Conclusions:Ribociclib and Abemaciclib prolonged QTcF Max >500 msec, especially at higher doses. Palbociclib had less QT prolongation and reduced QTcF at 125 mg. 12-hour ECG monitoring underscores the need for closer cardiac safety measures.Citation Format:Chia-Lun Chang, Wan-Chen Hsieh, Wei-Wen Chang, Ping-Kun Hsiao, Mao-Chih Hsieh, Tzeon-Jye Chiou, Tzu-Yao Liao, H-Eugene Liu, Hsin-Hsien Yu, Chih-Hsin Lee. QT prolongation induced by CDK-4/6 inhibitors in breast cancer: A prospective cohort study utilizing 12-hour continuous ECG monitoring [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 788.

2025-02-01·Journal of Microbiology, Immunology and Infection

Recommendation for the use of respiratory syncytial virus vaccines

Review

作者: Lee, Ping-Ing ; Lin, Yi-Tsung ; Huang, Yhu-Chering ; Lu, Chun-Yi ; Chang, Feng-Yee ; Chen, Yee-Chun ; Chiu, Cheng-Hsun ; Chi, Hsin ; Ku, Shih-Chi ; Chen, Po-Yen ; Hsueh, Po-Ren ; Yen, Muh-Yong ; Hu, Ya-Li ; Yen, Ting-Yu ; Liu, Ching-Chuan ; Chiu, Nan-Chang ; Lu, Chin-Te ; Hwang, Kao-Pin ; Lee, Wen-Sen ; Yang, Kuang-Yao ; Lin, Tzou-Yien ; Lin, Ying-Chin ; Hsu, Jen-Fu ; Chen, Shee-Uan ; Chen, Chih-Jung

Respiratory syncytial virus (RSV) is the most common pathogen for young children hospitalized with bronchiolitis and pneumonia. Most infections occur below 1 year of age. RSV is also a significant viral pathogen for adults with respiratory tract infection. Vaccines targeting the pre-fusion protein of RSV, including recombinant and mRNA vaccines, are now available. A committee of experts from related fields was convened by the Taiwan Immunization Vision and Strategy to develop recommendations for RSV vaccination in the elderly and pregnant women. The recommendation is not intended as a sole source of guidance in the prevention of RSV infection in children. The provisions listed in this recommendation are comprehensive suggestions made by experts in Taiwan based on existing medical evidence. This recommendation should be subject to modification in light of additional medical research findings in the future, and these provisions should not be cited as a basis for dispute resolution.

2025-02-01·Clinical Toxicology

Refractory methemoglobinemia after ingestion of N,N -dimethyl- p -toluidine

Article

作者: Chen, Hsien-Yi ; Mao, Chih-Yang ; Weng, Te-I ; Liao, Yen-Syuan

项与 Taipei Municipal Wanfang Hospital 相关的新闻（医药）

2024-12-16

·PRNewswire

Microbio Co., Ltd. (4128) Announces Promising Results of "MS-20" in Combination with Keytruda for Stage IIIb/IV Non-Small Cell Lung Cancer

CUPERTINO, Calif., Dec. 16, 2024 /PRNewswire/ -- Microbio Co., Ltd. (4128) today revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage IIIb/IV non-small cell lung cancer (NSCLC). The trial showed a threefold increase in the objective response rate (ORR) for the MS-20-Keytruda group (75%) compared to Keytruda alone (25%). Additionally, the median progression-free survival (PFS) for MS-20 patients improved from 4.5 months to over 12 months, with a complete response (CR) rate of 12.5%. Enhancing Immunotherapy with MS-20 MS-20, developed by Microbio, is a microbiome-based postbiotic designed to improve cancer immunotherapy by modulating the gut microbiome. "The results support MS-20's potential to reshape the microbiome and enhance Keytruda's effectiveness in treating advanced NSCLC," said Dr. Wan-Jiun Chen, Executive VP of Research & Development at Microbio. "Currently, hundreds of ongoing trials are aimed to find novel therapeutic agents for improving the efficacy of cancer immunotherapy, and this proof-of-concept trial supports the use of MS-20 in such application." This randomized, double-blind, placebo-controlled trial involved 15 patients, with 12 analyzed in the modified intent-to-treat (mITT) population (ClinicalTrials.gov ID: NCT04909034). Of the 8 patients receiving MS-20 and Keytruda, 6 (75% ORR) responded positively, including 1 with an ongoing CR lasting over 22 months and 5 with partial responses (PR). In contrast, only 1 of 4 patients in the placebo and Keytruda group showed a PR (25% ORR). The median PFS for the MS-20-Keytruda group was over 12 months, compared to 4.5 months in the placebo group. Scientific Insights and Next Steps Preclinical research published in Gut Microbes earlier this year supported these findings, showing that MS-20 enhances immune responses by increasing effector CD8 T cells in the tumor microenvironment. Microbio plans to use these results to pursue global collaborations and further its microbiome-based cancer immunotherapy platform. About Microbio Co., Ltd. Microbio (MB, Est. 2000) is a company focused on immune, oncology and metabolic diseases. In addition, MB is specialized in research and development into microbiome via its unique microbial pharmaceutical technology platforms. Its proprietary library with hundreds of unique anaerobic commensal bacteria metabolites has obtained significant findings in treatment of immune, oncology and metabolic diseases which takes it a further step into next-generation microbiome-based therapeutics. About MS-20 MS-20 is a postbiotic developed through Microbio's Symbiota™ fermentation technology involving symbiotic fermentation with multi-strain probiotics under an anaerobic condition. It is clinically proven to alleviate chemotherapy side effects and enhance immunotherapy efficacy. In 2024, MS-20 received an independent/self-affirmed GRAS status in the U.S. and is used in various food and beverages, including specialized medical nutrition products. For more information, visit or meet the team at the JPMorgan Healthcare Conference in San Francisco from January 13-16, 2025. SOURCE Microbio Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED